ManagementArriVent's management team is experienced, with the CEO having a successful track record, enhancing confidence in the company's strategic direction.
Product DevelopmentArriVent Biopharma is leading the development of a chemo-sparing oral EGFR TKI treatment for NSCLC with promising safety compared to current standards.
Stock PerformanceArriVent BioPharma, Inc. is up 45% in the last 2 months leading into the Ph 1b EGFR PACC mut NSCLC data.